189 related articles for article (PubMed ID: 34522200)
1. Quinazoline analogues as cytotoxic agents; QSAR, docking, and
Emami L; Sabet R; Khabnadideh S; Faghih Z; Thayori P
Res Pharm Sci; 2021 Oct; 16(5):528-546. PubMed ID: 34522200
[TBL] [Abstract][Full Text] [Related]
2. In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.
Asadollahi-Baboli M
Mol Divers; 2016 Aug; 20(3):729-39. PubMed ID: 27209475
[TBL] [Abstract][Full Text] [Related]
3. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
4. 6-Bromo quinazoline derivatives as cytotoxic agents: design, synthesis, molecular docking and MD simulation.
Emami L; Hassani M; Mardaneh P; Zare F; Saeedi M; Emami M; Khabnadideh S; Sadeghian S
BMC Chem; 2024 Jul; 18(1):125. PubMed ID: 38965630
[TBL] [Abstract][Full Text] [Related]
5. Computational Studies of bis-2-Oxoindoline Succinohydrazides and their In Vitro Cytotoxicity.
Jarapula R; Badavath VN; Rekulapally S; Manda S
Curr Comput Aided Drug Des; 2020; 16(3):270-280. PubMed ID: 30652647
[TBL] [Abstract][Full Text] [Related]
6. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
[TBL] [Abstract][Full Text] [Related]
7. Combined 3D-QSAR modeling and molecular docking study on multi-acting quinazoline derivatives as HER2 kinase inhibitors.
Mirzaie S; Monajjemi M; Hakhamaneshi MS; Fathi F; Jamalan M
EXCLI J; 2013; 12():130-43. PubMed ID: 26417222
[TBL] [Abstract][Full Text] [Related]
8. A Comparative QSAR Analysis, Molecular Docking and PLIF Studies of Some N-arylphenyl-2, 2-Dichloroacetamide Analogues as Anticancer Agents.
Fereidoonnezhad M; Faghih Z; Mojaddami A; Rezaei Z; Sakhteman A
Iran J Pharm Res; 2017; 16(3):981-998. PubMed ID: 29535790
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore & QSAR Guided Design, Synthesis, Pharmacokinetics and
Alam S; Verma S; Fatima K; Luqman S; Srivastava SK; Khan F
Curr Med Chem; 2024; 31(5):620-639. PubMed ID: 37132141
[TBL] [Abstract][Full Text] [Related]
10. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic Evaluation, Molecular Docking, and 2D-QSAR Studies of Dihydropyrimidinone Derivatives as Potential Anticancer Agents.
Altaf R; Nadeem H; Ilyas U; Iqbal J; Paracha RZ; Zafar H; Paiva-Santos AC; Sulaiman M; Raza F
J Oncol; 2022; 2022():7715689. PubMed ID: 35509846
[TBL] [Abstract][Full Text] [Related]
12. Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis.
Sudha A; Srinivasan P; Rameshthangam P
J Recept Signal Transduct Res; 2015 Apr; 35(2):137-48. PubMed ID: 25069678
[TBL] [Abstract][Full Text] [Related]
13. A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.
Panigrahi D; Mishra A; Sahu SK; Azam MA; Vyshaag CM
Med Chem; 2022; 18(1):51-87. PubMed ID: 33319692
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profiling of quinazoline-4(3H)-one analogs as EGFR inhibitors: 3D-QSAR modeling, molecular docking studies and the design of therapeutic agents.
Abdullahi SH; Uzairu A; Shallangwa GA; Uba S; Umar AB
J Taibah Univ Med Sci; 2023 Oct; 18(5):1018-1029. PubMed ID: 36959916
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of 2,3-dihydro-[1,4]dioxino[2,3-f]quinazoline derivatives as EGFR inhibitors.
Qin X; Yang L; Liu P; Yang L; Chen L; Hu L; Jiang M
Bioorg Chem; 2021 May; 110():104743. PubMed ID: 33714020
[TBL] [Abstract][Full Text] [Related]
17. Multi-target QSAR and docking study of steroids binding to corticosteroid-binding globulin and sex hormone-binding globulin.
Nikolic K; Filipic S; Agbaba D
Curr Comput Aided Drug Des; 2012 Dec; 8(4):296-308. PubMed ID: 22242800
[TBL] [Abstract][Full Text] [Related]
18. 3D,2D-QSAR study and docking of novel quinazolines as potential target drugs for osteosarcoma.
Lian Z; Sang C; Li N; Zhai H; Bai W
Front Pharmacol; 2023; 14():1124895. PubMed ID: 36895941
[No Abstract] [Full Text] [Related]
19. Molecular Docking and QSAR Study of 2-Benzoxazolinone, Quinazoline and Diazocoumarin Derivatives as Anti-HIV-1 Agents.
Kamyar K; Safakish M; Zebardast T; Hajimahdi Z; Zarghi A
Iran J Pharm Res; 2019; 18(3):1253-1263. PubMed ID: 32641936
[TBL] [Abstract][Full Text] [Related]
20. Exploration of 2D and 3D-QSAR analysis and docking studies for novel dihydropteridone derivatives as promising therapeutic agents targeting glioblastoma.
Pan M; Cheng L; Wang Y; Lyu C; Hou C; Zhang Q
Front Pharmacol; 2023; 14():1249041. PubMed ID: 37719847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
